Arthrogryposis

14 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Treatments and conditions

Arthrogryposis
Treatment and conditionWhere it standsTrials
ALK-inhibitor or RET-inhibitor + BNT116 for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
anti-HER3 antibody conjugated to topoisomerase I inhibitor + BNT116 for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT116 for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT116 + BNT316 for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT116 + CEMIPLIMAB for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT116 + CEMIPLIMAB + Carboplatin + Paclitaxel for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT116 + DOCETAXEL for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT116 + OSIMERTINIB for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT116 + Pumitamig for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT116 + Tambotatug Pelitecan for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT326 for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT326 + ITRACONAZOLE for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT326 + Paroxetine for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT326 + Pumitamig for arthrogryposisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.